SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2024


Years Ended December 31,	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(in millions, except per share data)
2024
Net sales	$	1,329.9	$	1,369.4	$	1,354.4	$	1,385.8	$	5,439.5
Gross profit	1,043.0		1,093.9		1,091.5		1,093.6		4,322.0
Income from continuing operations, net of tax	324.9		364.0		362.1		345.0		1,396.0
Income from discontinued operations, net of tax (a)	26.1		1.0		2,707.3		39.3		2,773.7
Net income (a)	351.0		365.0		3,069.4		384.3		4,169.7
Net income attributable to Edwards Lifesciences Corporation (a)	351.9		366.3		3,070.8		385.6		4,174.6
Basic earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.53		0.07		4.64
Basic earnings per share	0.58		0.61		5.14		0.65		6.98
Diluted earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.52		0.07		4.63
Diluted earnings per share	0.58		0.61		5.13		0.65		6.97
2023
Net sales	$	1,221.3	$	1,278.9	$	1,243.4	$	1,266.4	$	5,010.0
Gross profit	992.3		1,031.1		992.8		1,015.4		4,031.6
Income from continuing operations	300.6		251.4		334.9		333.1		1,220.0
Income from discontinued operations, net of tax	39.9		54.1		48.8		36.6		179.4
Net income	340.5		305.5		383.7		369.7		1,399.4
Net income attributable to Edwards Lifesciences Corporation	340.5		307.1		384.9		369.9		1,402.4
Basic earnings per share:
Continuing operations	0.49		0.42		0.55		0.55		2.02
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Basic earnings per share	0.56		0.51		0.63		0.61		2.31
Diluted earnings per share:
Continuing operations	0.49		0.41		0.55		0.55		2.01
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Diluted earnings per share	0.56		0.50		0.63		0.61		2.30

_______________________________________________________________________________

(a) The third quarter of 2024 includes a $3.3 billion gain from the sale of Critical Care. See Note 5 for additional information.